Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
skin sensitisation: in vivo (LLNA)
Type of information:
experimental study
Adequacy of study:
key study
Study period:
2013-04-04 to 2013-07-05
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: GLP guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2013
Report date:
2013

Materials and methods

Test guidelineopen allclose all
Qualifier:
according to guideline
Guideline:
OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
Deviations:
no
Qualifier:
according to guideline
Guideline:
EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
Deviations:
no
Qualifier:
according to guideline
Guideline:
EPA OPPTS 870.2600 (Skin Sensitisation)
Deviations:
no
GLP compliance:
yes (incl. QA statement)
Remarks:
(Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, München, Germany)
Type of study:
mouse local lymph node assay (LLNA)

Test material

Constituent 1
Reference substance name:
Acid Red RN 2949
IUPAC Name:
Acid Red RN 2949
Test material form:
solid: particulate/powder
Remarks:
migrated information: powder
Details on test material:
Name: Acid Red RN 2949
Batch No.: RN 2949 Reg
Chemical Name: 1-naphthalenesulfonic acid, 3,3´-[(phenylmethylene)-bis[(2-methoxy-4,1-phenylene)-2,1-diazenediyl]]bis[4-hydroxy-, disodium salt
Formula C41H30N4Na2O10S2
Physical State: powder
Colour: dark red
pH: 6-8
Molecular Weight: 848.82 g/mol
Content / Purity: 100 % (composition see AZ. No. 12-2302/4928 vl., dated 2012-08-28)
Storage Conditions: room temperature
Expiry Date: 05.03.2015
Safety Precautions: The routine hygienic procedures were sufficient to assure personnel health and safety.

In vivo test system

Test animals

Species:
mouse
Strain:
CBA
Sex:
female
Details on test animals and environmental conditions:
- Full barrier in an air-conditioned room
- Temperature: 22 ± 3 °C
- Relative humidity: 55 ± 10%
- Artificial light, sequence being 12 hours light, 12 hours dark
- Air change: at least 10 x / hour
- Free access to Altromin 1324 maintenance diet for rats and mice (lot no. 0902)
- Free access to tap water, sulphur acidified to a pH value of approx. 2.8 (drinking water, municipal residue control, microbiological controls at
regular intervals)
- The animals were kept in groups of 5 animals in IVC cages, type II L, polysulphone cages on Altromin saw fibre bedding
(prescreen test: lot no. 011012, main study: lot no. 240113)
- Certificates of food, water and bedding are filed at BSL BIOSERVICE
- Adequate acclimatisation period (at least five days) under laboratory conditions

Study design: in vivo (LLNA)

Vehicle:
other: 2% carboxymethylcellulose (CMC) in aqua ad inject.
Concentration:
Based on the results observed in the prescreen test the following test item concentrations were selected for the main study:
1.5%, 3% and 6% (w/v).
Due to the solubility properties of the test item 2% carboxymethylcellulose (CMC) in aqua ad inject. was used as vehicle.





No. of animals per dose:
5 animals/dose group, 5 animals/control group
Details on study design:
Prescreen Test
Before the initiation of the prescreen test, a solubility test was performed to define the vehicle and the maximum concentration which is technically
applicable to the animals.
The maximum technically applicable concentration of the test item in the vehicle was found to be 6% in 2% CMC in aqua ad inject.
In order to determine the highest tolerated and not excessively irritant test concentration a prescreen test was performed which was conducted under the same conditions as the main study, except there was no assessment of lymph node proliferation. The mice were observed daily for any clinical signs of systemic toxicity or local irritation at the application site. Body weights were recorded pre-test and prior to termination. Both ears were
observed for erythema and scored. Ear thickness measurements were performed on day 1 (pre-dose), day 3 (approximately 48 hours after the first dose) and day 6. Excessive local irritation was indicated by an erythema score ≥ 3 and/or ear swelling of ≥ 25%.
Two animals were treated by topical application with the test item on three consecutive days at a concentration of 6% (dissolved in 2% CMC) to the entire dorsal surface of each ear.
One further animal was treated with 2% CMC (undiluted) and served as negative control.
Immediately before the first application, approximately 48 hours after the first application and shortly before sacrificing the thickness of both ears of all animals was measured.
During this period also all clinical signs were recorded.
Cageside observations included spontaneous activity, lethargy, recumbent position, convulsions, tremors, apnoea, asphyxia, vocalisation, diarrhoea, changes in the skin and fur, eyes and mucous membranes (salivation, discharge).
Neither signs of systemic toxicity nor signs of irritation at the application site could be detected in any animal.
All animals showed the expected weight development, which includes a weight loss of up to 2 g throughout the duration of the prescreen test.

Main Study

Preparation of the Animals
The animals were randomly selected.
Identification was ensured by cage number and individual marking (tail).

Clinical Observation
Prior to the application and once a day thereafter all animals were observed in order to detect signs of toxicity, including dermal irritation at site of
application.

Weight Assessment
The animals were weighed prior to the application and at the end of the test period (prior to the treatment with 3HTdR).

Dose Groups
3 test groups (3 different concentrations), 1 negative control group (vehicle) and 1 positive control group were tested.

Test Regime
Topical Application
Immediately before the first application the thickness of both ears of all animals was measured. Each mouse was treated by topical application of
25 µL of the selected solution to the entire dorsal surface of each ear. A second measurement of the ear thickness of all animals was carried out
approximately 48 hours after the first application.
Topical applications were performed once daily over three consecutive days.
Administration of 3H-Methyl Thymidine
Five days after the first topical application all mice were dosed with 20 µCi 3H-methyl thymidine by intravenous injection (tail vein) of 250 µL of
3H-methyl thymidine, diluted to a working concentration of 80 µCi/mL.
Preparation of Cell Suspension
Approximately 5 hours after the injection of 3H-methyl thymidine all mice were sacrificed by cervical dislocation. Shortly before sacrificing the thickness of the ears of all animals was measured for a third time. The draining auricular lymph nodes were excised, individually pooled for each animal
(2 lymph nodes per animal) and collected in phosphate buffered saline (PBS). A single cell suspension of pooled lymph node cells  
was prepared by gentle mechanical disaggregation through polyamide gauze (200 mesh size). After washing the gauze with PBS the cell suspension was pelleted in a centrifuge. The supernatant was discarded and the pellets were resuspended with PBS. This washing procedure was repeated.
After the final wash each pellet was resuspended in approx. 1 mL 5% TCA at approx. 4° C for approximately 18 hours for precipitation of
macromolecules. Each precipitate was once washed again, resuspended in 1 mL 5% TCA and 7 mL scintillation fluid was added. Then this solution
was transferred into scintillation vials and stored at room temperature overnight.
Determination of Incorporated 3H-Methyl Thymidine
The 3H-methyl thymidine – incorporation was measured in a ß-counter and expressed as the number of disintegrations per minute (DPM). Similarly, background 3H-methyl thymidine levels were also measured (5% TCA). Determination of radioactivity was performed individually for each animal.


Evaluation of Results
The proliferative response of lymph node cells was expressed as the number of radioactive disintegrations per minute per lymph node (DPM/NODE) and as the ratio of 3H-methyl thymidine - incorporation into lymph node cells of test group animals relative to that recorded for control group
animals (STIMULATION INDEX). Before DPM/NODE values were determined, background values were subtracted.
EC3 values, calculated concentrations which induce stimulation indices of three, are determined by linear interpolation {EC3=c+[(3-d)/(b-d)]x(a c)}, between two points of the stimulation indices axis, one above (a,b) and one below (c,d) the stimulation index of three. If all measured points are above or below the stimulation index of three, no EC3 value can be stated.
A substance is regarded as a 'sensitiser' in the LLNA if at least one concentration of the test item results in a 3-fold or greater increase in 3H-methyl thymidine - incorporation into lymph node cells of the test group animals, relative to that recorded for the lymph nodes of control group animals
(Stimulation Index equal to or greater than 3.0).
Positive control substance(s):
hexyl cinnamic aldehyde (CAS No 101-86-0)
Statistics:
Outlier tests according to Dixon, Grubbs and Nalimov were performed for the values measured for the number of disintegrations per minute (DPM). If outliers were identified, these values were not included in the calculation of the stimulation indices. As at least four values per group are required for the evaluation of the results, the outlier test was not repeated to detect further outliers.

Results and discussion

Positive control results:
The stimulation index of the positive control (25% α-Hexylcinnamaldehyde in 2% CMC in aqua ad injectionem ) was 9.1.

In vivo (LLNA)

Resultsopen allclose all
Parameter:
SI
Remarks on result:
other: see Remark
Remarks:
None of the three tested concentrations of the test item reached the stimulation index of 3. The stimulation index at a concentration of 1.5% was 0.9 The stimulation index at a concentration of 3% was 1.0 The stimulation index at a concentration of 6% was 1.3
Parameter:
other: disintegrations per minute (DPM)
Remarks on result:
other: see Remark
Remarks:
Conc. [%] Animal number DPM DPM- mean back- ground 100 16 1187.0 1166.0 17 1670.0 1649.0 18 659.0 638.0 19 523.0 502.0 20 651.0 630.0 MV 938.0 917.0 SD 431.3 431.3 25 21 7557.0 7536.0 22 5424.0 5403.0 23 10658.0 10637.0 24 11852.0 11831.0 25 6354.0 6333.0 MV 8369.0 8348.0 SD 2480.5 2480.5 1.5 1 642.0 621.0 2 755.0 734.0 3 893.0 872.0 4 1572.0* n.d. 5 1006.0 985.0 MV 824.0 803.0 SD 137.6 137.6 3 6 957.0 936.0 7 981.0 960.0 8 925.0 904.0 9 608.0** n.d. 10 864.0 843.0 MV 931.8 910.8 SD 43.9 43.9 6 11 823.0 802.0 12 1528.0 1507.0 13 1012.0 991.0 14 1514.0 1493.0 15 1154.0 1133.0 MV 1206.2 1185.2 SD 277.7 277.7 22.0 18.0 24.0 19.0 22.0 MV 21.0 0.0 SD 2.2 * = outlier, failed Nalimov; ** = outlier, failed Grubbs, Nalimov and Dixon; n.d. = not determined

Any other information on results incl. tables

Table Ear Thickness – Preliminary Test (mm)

  Animal No. Measurement of Ear Thickness (mm)
Concentration Day 1 Day 3 Day 6
  left right left right left right
Acid Red RN 294
6% in CMC (2%)
1 0.18 0.18 0.18 0.17 0.17 0.17
         
Acid Red RN 294
6% in CMC (2%)
2 0.18 0.18 0.17 0.17 0.18 0.18
         
Negative Control
100% CMC (2%)
3 0.18 0.18 0.17 0.17 0.17 0.17

Table Absolute Body Weights – Preliminary Test (g)

Concentration Animal
No.
Start
of Study
End
of Study
Weight
Gain
Acid Red RN 294
6% in CMC (2%)
1 21 21 0
         
Acid Red RN 294
6% in CMC (2%)
2 24 23 -1
         
Negative Control
100% CMC (2%)
3 22 23 1

Table Radioactive Determination of the Test Substance and Control Groups

POS CPM     Test Item Conc. [%] Animal number DPM DPM- mean back- ground DPM/ Node Stimu-lation Index
56 571.0     Negative 100 16 1187.0 1166.0 583.0  
57 805.0      Control   17 1670.0 1649.0 824.5  
58 319.0      CMC (2%)   18 659.0 638.0 319.0  
59 253.0         19 523.0 502.0 251.0  
60 311.0         20 651.0 630.0 315.0  
MV 451.8         MV 938.0 917.0 458.5 1.0
SD 207.8         SD 431.3 431.3 215.7  
61 3649.0     Positive 25 21 7557.0 7536.0 3768.0 8.2
62 2545.0     Control   22 5424.0 5403.0 2701.5 5.9
63 5105.0     α-Hexylcinnamaldehyde   23 10658.0 10637.0 5318.5 11.6
64 5652.0     in CMC (2%)   24 11852.0 11831.0 5915.5 12.9
65 3066.0         25 6354.0 6333.0 3166.5 6.9
MV 4003.4         MV 8369.0 8348.0 4174.0 9.1
SD 1188.5         SD 2480.5 2480.5 1240.2 2.7
41 311.0     Acid Red RN 2949 1.5 1 642.0 621.0 310.5 0.7
42 350.0     in CMC (2%)   2 755.0 734.0 367.0 0.8
43 417.0         3 893.0 872.0 436.0 1.0
44 762.0*         4 1572.0* n.d. n.d. n.d.
45 489.0         5 1006.0 985.0 492.5 1.1
MV 391.8         MV 824.0 803.0 401.5 0.9
SD 67.7         SD 137.6 137.6 68.8 0.2
46 466.0     Acid Red RN 2949 3 6 957.0 936.0 468.0 1.0
47 476.0     in CMC (2%)   7 981.0 960.0 480.0 1.0
48 449.0         8 925.0 904.0 452.0 1.0
49 296.0**         9 608.0** n.d. n.d. n.d.
50 422.0         10 864.0 843.0 421.5 0.9
MV 453.3         MV 931.8 910.8 455.4 1.0
SD 20.5         SD 43.9 43.9 21.9 0.0
51 399.0     Acid Red RN 2949 6 11 823.0 802.0 401.0 0.9
52 735.0     in CMC (2%)   12 1528.0 1507.0 753.5 1.6
53 490.0         13 1012.0 991.0 495.5 1.1
54 723.0         14 1514.0 1493.0 746.5 1.6
55 560.0         15 1154.0 1133.0 566.5 1.2
MV 581.4         MV 1206.2 1185.2 592.6 1.3
SD 130.9         SD 277.7 277.7 138.8 0.3
81 11.0     Background     22.0      
82 9.0     Szinti and     18.0      
83 12.0     TCA     24.0      
84 9.0           19.0      
85 11.0           22.0      
MV 10.4         MV 21.0 0.0 0.0 0.0
SD 1.2         SD 2.2      
* = outlier, failed Nalimov;  ** = outlier, failed Grubbs, Nalimov and Dixon;  n.d. = not determined

Table Absolute Body Weights in g

Concentration Animal
No.
Start
of Study
End
of Study
Weight
Gain
  1 22 23 1
Acid Red RN 294 2 21 22 1
  3 21 22 1
1.5% in CMC (2%) 4 22 23 1
  5 20 22 2
         
  6 19 21 2
Acid Red RN 294 7 19 21 2
  8 22 23 1
3% in CMC (2%) 9 18 19 1
  10 19 20 1
         
  11 22 23 1
Acid Red RN 294 12 20 21 1
  13 20 21 1
6% in CMC (2%) 14 20 22 2
  15 20 21 1
         
  16 20 22 2
Negative Control 17 19 20 1
  18 20 22 2
100% CMC (2%) 19 18 21 3
  20 21 23 2
         
Positive Control
25% α-Hexyl-
cinnamaldehyde
in CMC (2%)
21 22 23 1
22 19 21 2
23 21 22 1
24 20 20 0
25 19 20 1

Table Clinical Observation

Time of Observation

Systemic Effects

Local Effects

Group 1, animals no. 1 – 5 / test item at a concentration of 1.5%in CMC (2%)

Day 1

nsf

nsf

Day2

nsf

nsf

Day 3

nsf

nsf

Day 4

nsf

nsf

Day 5

nsf

nsf

Day 6

nsf

nsf

Group 2, animals no. 6 – 10 / test item at a concentration of 3%in CMC (2%)

Day 1

nsf

nsf

Day2

nsf

nsf

Day3

nsf

nsf

Day4

nsf

nsf

Day5

nsf

nsf

Day6

nsf

nsf

Group 3, animals no. 11 – 15 / test item at a concentration of 6%in CMC (2%)

Day 1

nsf

nsf

Day2

nsf

nsf

Day3

nsf

nsf

Day4

nsf

nsf

Day5

nsf

nsf

Day6

nsf

nsf

Group 4, animals no. 16 – 20 / negative control100% CMC (2%)

Day 1

nsf

nsf

Day2

nsf

nsf

Day3

nsf

nsf

Day4

nsf

nsf

Day5

nsf

nsf

Day6

nsf

nsf

Group 5, animals no. 21 – 25 / positive control 25%in CMC (2%)

Day 1

nsf

nsf

Day2

nsf

nsf

Day3

nsf

nsf

Day4

nsf

nsf

Day5

nsf

nsf

Day6

nsf

nsf

nsf = no specific findings

Applicant's summary and conclusion

Interpretation of results:
GHS criteria not met
Remarks:
Migrated information
Conclusions:
The EC3 value (derived by linear interpolation) could not be calculated as the stimulation indices of all concentrations were below 3.
The results of radioactivity determination were supported by the means of the ear thickness per group, which showed no relevant difference
compared to the negative control.
Consequently, according to OECD 429 the test item Acid Red RN 2949 as described in this report is expected to have no sensitising properties
and therefore should not be regarded as a dermal sensitiser.
Executive summary:

Based on the results of the prescreen test the test item was assessed for sensitising properties at concentrations of 1.5%, 3% and 6% (w/v), each diluted with2% carboxymethylcellulose (CMC) in aqua ad inject. The concentration of 6% in 2% CMC in

aqua ad inject was the maximum technically applicable concentration of the test item in the vehicle.

At the daily clinical observation the animals did not show any visible clinical symptoms and no case of mortality was observed.Species/strain:                     Mice, CBA/CaOlaHsd

Number of animals:            25/main test, 3/prescreen test

Vehicle:                               2% carboxymethylcellulose (CMC) in aqua ad inject

Summary Results

None of the three tested concentrations of the test item reached the stimulation index of 3.

The stimulation index at a concentration          of       1.5%   was     0.9

The stimulation index at a concentration          of       3%      was     1.0

The stimulation index at a concentration          of       6%      was     1.3

 

The mean ear thickness on

day 1

day 3

day 6

for the 1.5% test group was

0.19 mm

0.19 mm

0.19 mm

for the 3% test group was

0.18 mm

0.19 mm

0.20 mm

for the 6% test group was

0.19 mm

0.20 mm

0.20 mm

for the negative control group was

0.19 mm

0.19 mm

0.19 mm

for the positive control group was

0.19 mm

0.21 mm

0.21 mm

The stimulation index of the positive control (25% α-Hexylcinnamaldehyde in2% CMC in aqua ad injectionem) was 9.1 and therefore the test is considered to be valid.


 

Conclusion

The EC3 value (derived by linear interpolation) could not be calculated as the stimulation indices of all concentrations were below 3.

The results of radioactivity determination were supported by the means of the ear thickness per group, which showed no relevant difference compared to the negative control.

Consequently, according to OECD 429[3]the test item Acid Red RN 2949 as described in this report is expected to have no sensitising properties and therefore should not be regarded as a dermal sensitiser.